Page 988 - Williams Hematology ( PDFDrive )

962 Part VII: Neutrophils, Eosinophils, Basophils, and Mast Cells Chapter 62: Eosinophils and Related Disorders 963

165. Arefi M, Robledo C, Penarrubia MJ, et al: Genomic analysis of clonal eosinophils 185. Pitini V, Arrigo C, Azzarello D, et al: Serum concentration of cardiac Troponin T in
by CGH arrays reveals new genetic regions involved in chronic eosinophilia. Eur J patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse
Haematol 93:422–428, 2014. outcomes. Blood 102:3456–3457; author reply 3457, 2003.
166. Sadovnik I, Lierman E, Peter B, et al: Identification of Ponatinib as a potent inhibitor of 186. Garrett JK, Jameson SC, Thomson B, et al: Anti-interleukin-5 (mepolizumab) therapy
growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. for hypereosinophilic syndromes. J Allergy Clin Immunol 113:115–119, 2004.
Exp Hematol 42:282–293.e4, 2014. 187. Klion AD, Law MA, Noel P, et al: Safety and efficacy of the monoclonal anti-inter-
167. Klion AD, Noel P, Akin C, et al: Elevated serum tryptase levels identify a subset of leukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syn-
patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome drome. Blood 103:2939–2941, 2004.
associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 188. Gotlib J, Cools J, Malone JM 3rd, et al: The FIP1L1-PDGFRalpha fusion tyrosine kinase
101:4660–4666, 2003. in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for
168. Lefevre G, Copin MC, Staumont-Salle D, et al: The lymphoid variant of hypereosin- diagnosis, classification, and management. Blood 103:2879–2891, 2004.
ophilic syndrome: Study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. 189. Posada de la Paz M, Philen RM, Borda AI: Toxic oil syndrome: The perspective after 20
Medicine (Baltimore) 93:255–266, 2014. years. Epidemiol Rev 23:231–247, 2001.
169. Roufosse F, Cogan E, Goldman M: Lymphocytic variant hypereosinophilic syndromes. 190. Andersen CL, Siersma VD, Hasselbalch HC, et al: Association of the blood eosinophil
Immunol Allergy Clin North Am 27:389–413, 2007. count with hematological malignancies and mortality. Am J Hematol 90:225–229, 2015.
170. Cogan E, Schandene L, Crusiaux A, et al: Brief report: Clonal proliferation of type 191. Davis BP, Rothenberg ME: Eosinophils and cancer. Cancer Immunol Res 2:1–8, 2014.
2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 330: 192. Harbaum L, Pollheimer MJ, Kornprat P, et al: Peritumoral eosinophils predict recur-
535–538, 1994. rence in colorectal cancer. Mod Pathol 28:403–413, 2015.
171. Simon HU, Plotz SG, Dummer R, et al: Abnormal clones of T cells producing interleu- 193. Wong DT, Bowen SM, Elovic A, et al: Eosinophil ablation and tumor development. Oral
kin-5 in idiopathic eosinophilia. N Engl J Med 341:1112–1120, 1999. Oncol 35:496–501, 1999.
172. Roufosse F, Schandene L, Sibille C, et al: Clonal Th2 lymphocytes in patients with the 194. Sable-Fourtassou R, Cohen P, Mahr A, et al: Antineutrophil cytoplasmic antibodies and
idiopathic hypereosinophilic syndrome. Br J Haematol 109:540–548, 2000. the Churg-Strauss syndrome. Ann Intern Med 143:632–638, 2005.
173. Roufosse F, Cogan E, Goldman M: Recent advances in pathogenesis and management 195. Kallenberg CG: Churg-Strauss syndrome: Just one disease entity? Arthritis Rheum
of hypereosinophilic syndromes. Allergy 59:673–689, 2004. 52:2589–2593, 2005.
174. Spry CJF: The idiopathic hypereosinophilic syndrome, in Eosinophils, Biological and 196. Comarmond C, Pagnoux C, Khellaf M, et al: Eosinophilic granulomatosis with polyangi-
Clinical Aspects, edited by Makino S, Fukuda T. CRC Press, Boca Raton, FL, 1991. itis (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients
175. Davis RF, Dusanjh P, Majid A, et al: Eosinophilic cellulitis as a presenting feature of enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65:270–281, 2013.
chronic eosinophilic leukaemia, secondary to a deletion on chromosome 4q12 creating 197. Mouthon L, Dunogue B, Guillevin L: Diagnosis and classification of eosinophilic gran-
the FIP1L1-PDGFRA fusion gene. Br J Dermatol 155:1087–1089, 2006. ulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun
176. Khoury P, Grayson PC, Klion AD: Eosinophils in vasculitis: Characteristics and roles in 48–49:99–103, 2014.
pathogenesis. Nat Rev Rheumatol 10:474–483, 2014. 198. Lane SE, Watts RA, Bentham G, et al: Are environmental factors important in primary
177. Klion AD, Law MA, Riemenschneider W, et al: Familial eosinophilia: A benign disor- systemic vasculitis? A case-control study. Arthritis Rheum 48:814–823, 2003.
der? Blood 103:4050–4055, 2004. 199. Guillevin L, Pagnoux C, Seror R, et al: The five-factor score revisited: Assessment of
178. Gleich GJ, Leiferman KM: The hypereosinophilic syndromes: Current concepts and prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study
treatments. Br J Haematol 145:271–285, 2009. Group (FVSG) cohort. Medicine (Baltimore) 90:19–27, 2011.
179. Legrand F, Renneville A, Macintyre E, et al: The spectrum of FIP1L1-PDGFRA- 200. Kallenberg CG: Key advances in the clinical approach to ANCA-associated vasculitis.
associated chronic eosinophilic leukemia: New insights based on a survey of 44 cases. Nat Rev Rheumatol 10:484–493, 2014.
Medicine (Baltimore). 92(5):E1–E9, 2013. 201. Masi AT, Hunder GG, Lie JT, et al: The American College of Rheumatology 1990
180. Metzgeroth G, Walz C, Erben P, et al: Safety and efficacy of imatinib in chronic eosin- criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and
ophilic leukaemia and hypereosinophilic syndrome: A phase-II study. Br J Haematol angiitis). Arthritis Rheum 33:1094–1100, 1990.
143:707–715, 2008. 202. Khoury P, Zagallo P, Talar-Williams C, et al: Serum biomarkers are similar in Churg-
181. Jain N, Cortes J, Quintas-Cardama A, et al: Imatinib has limited therapeutic activity for Strauss syndrome and hypereosinophilic syndrome. Allergy 67:1149–1156, 2012.
hypereosinophilic syndrome patients with unknown or negative PDGFRalpha muta- 203. Pinal-Fernandez I, Selva-O’Callaghan A, Grau JM: Diagnosis and classification of eos-
tion status. Leuk Res 33:837–839, 2009. inophilic fasciitis. Autoimmun Rev 13:379–382, 2014.
182. Helbig G, Soja A, Bartkowska-Chrobok A, et al: Chronic eosinophilic leukemia-not 204. Martin RW, Duffy J, Lie JT: Eosinophilic fasciitis associated with use of L-tryptophan: A
otherwise specified has a poor prognosis with unresponsiveness to conventional treat- case-control study and comparison of clinical and histopathologic features. Mayo Clin
ment and high risk of acute transformation. Am J Hematol 87:643–645, 2012. Proc 66:892–898, 1991.
183. Salemi S, Yousefi S, Simon D, et al: A novel FIP1L1-PDGFRA mutant destabilizing 205. Berianu F, Cohen MD, Abril A, et al: Eosinophilic fasciitis: Clinical characteristics and
the inactive conformation of the kinase domain in chronic eosinophilic leukemia/ response to methotrexate. Int J Rheum Dis. 18(1):91–98, 2015.
hypereosinophilic syndrome. Allergy 64:913–918, 2009. 206. Corwin HL, Bray RA, Haber MH: The detection and interpretation of urinary eosino-
184. Cools J, Stover EH, Boulton CL, et al: PKC412 overcomes resistance to imatinib in a phils. Arch Pathol Lab Med 113:1256–1258, 1989.
murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 207. Hughes PA, Magnet AD, Fishbain JT: Eosinophilic meningitis: A case series report and
3:459–469, 2003. review of the literature. Mil Med 168:817–821, 2003.

Kaushansky_chapter 62_p0947-0964.indd 963 9/21/15 10:56 AM